A Study Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies



Status:Archived
Conditions:Cancer, Cancer
Therapuetic Areas:Oncology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:December 2008
End Date:November 2011

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase 1, Open-Label, Dose Escalation Study To Evaluate Safety, Pharmacokinetics And Pharmacodynamics Of PF-04554878 In Patients With Advanced Non-Hematologic Malignancies


Phase 1 safety, pharmacokinetics, and pharmacodynamics trial of the focal adhesion kinase
(FAK) inhibitor PF-04554878 in patients with advanced non-hematologic malignancies,
including patients with malignancies appropriate for serial biopsy. Screening consists of
medical history, physical examination ECOG performance status, blood draws, a pregnancy test
for female patients of childbearing potential, a FDG-PET and tumor imaging. Treatment
consists of PF-04554878 pills continued until progression of disease, unacceptable toxicity,
or patient request. Evaluations for bioactivity are measured by serial FDG-PET and blood
tests for biomarkers related to FAK and Pyk2 activities.



We found this trial at
2
sites
Darien Pediatric Associates
106 Noroton Ave
Darien, Connecticut 06820
(203) 655-9741
Darien Pediatric Associates Our office is pleased and privileged to care for your children and...
?
mi
from
Darien, CT
Click here to add this to my saved trials
Pfizer Investigational Site
Bristol, Tennessee 37620
?
mi
from
Bristol, TN
Click here to add this to my saved trials